Transverse Myelitis Trial, Recruiting (NCT06941584)

Transverse Myelitis Trial, Recruiting NCT06941584 Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS Condition: Transverse Myelitis

Printed from Voxsanity (voxsanity.com.au) — NCT06941584 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Transverse Myelitis

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You have been diagnosed with a condition called NMOSD (a disease affecting the brain and spinal cord) linked to a specific antibody called AQP4, and you also have at least one other autoimmune condition from a specific list (confirm with trial site)
You have been diagnosed with myasthenia gravis (a muscle weakness condition) linked to a specific antibody called AChR, and you also have at least one other autoimmune condition from a specific list (confirm with trial site)
You have been diagnosed with autoimmune encephalitis (brain inflammation caused by the immune system) linked to specific antibodies called LGI1 and CASPR2, and you also have at least one other autoimmune condition from a specific list (confirm with trial site)
You are an adult with a specific inherited gene change in a gene called AIRE that affects how the immune system works (confirm with trial site)

Who may not be able to join:

You currently have a thymoma (a tumour of the thymus gland) that has not been treated
You have had a thymoma in the past

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 28 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Raffaele Iorio, MD, Dipartimento di Neurologia - Policlinico Fondazione Agostino Gemelli

Phone: 3347185128

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06941584

Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Phase: Not Applicable

Status: Recruiting

Condition: Transverse Myelitis

Trial contact: 3347185128

More information: https://clinicaltrials.gov/study/NCT06941584

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You have been diagnosed with a condition called NMOSD (a disease affecting the brain and spinal cord) linked to a specific antibody called AQP4, and you also have at least one other autoimmune condition from a specific list (confirm with trial site)
You have been diagnosed with myasthenia gravis (a muscle weakness condition) linked to a specific antibody called AChR, and you also have at least one other autoimmune condition from a specific list (confirm with trial site)
You have been diagnosed with autoimmune encephalitis (brain inflammation caused by the immune system) linked to specific antibodies called LGI1 and CASPR2, and you also have at least one other autoimmune condition from a specific list (confirm with trial site)
You are an adult with a specific inherited gene change in a gene called AIRE that affects how the immune system works (confirm with trial site)

Who may not be able to join:

You currently have a thymoma (a tumour of the thymus gland) that has not been treated
You have had a thymoma in the past

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Registry

ClinicalTrials.gov

Start date

6 November 2024

Est. completion

6 January 2027

Where this trial is recruiting

🇮🇹 Italy

Primary endpoints

The role of AIRE in neurological autoimmune diseases

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov